中国埃克替尼治疗非小细胞肺癌专家共识（2016年版）

China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version) Yuankai SHI, Yan SUN, Cuimin DING, Ziping WANG, Changli WANG, Chong BAI, Chunxue BAI, Jifeng FENG, Xiaoqing LIU, Fang LI, Yue YANG, Yongqian SHU, Milu WU, Jianxing HE, Yiping ZHANG, Shucai ZHANG, Gongyan CHEN, Honghe LUO, Rongcheng LUO, Caicun ZHOU, Qingsong PANG, Xingsheng HU, Hong ZHAO, Qiong ZHAO, Aiqin GU, Yang LING, Cheng HUANG, Baohui HAN, Shunchang JIAO, Hong JIAN National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China; 2 The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China; Beijing Cancer Hospital, Beijing 100142, China; Tianjin Medical University Cancer Institute and Hospital, Tianjin 300070, China; The Second Military Medical University Changhai Hospital, Shanghai 200433, China; Fudan University Zhongshan Hospital, Shanghai 200032, China; Jiangsu Cancer Hospital, Nanjing 210009, China; The 307 Hospital of Chinese People's Liberation Army, Beijing 100071, China; Chinese People's Liberation Army General Hospital, Beijing 100853, China; Jiangsu Province Hospital, Nanjing 210029, China; Qinghai University Affiliated Hospital, Xining 810000, China; The First Affiliated Hospital of Guangzhou Medical Unversity, Guangzhou 510000, China; Zhejiang Cancer Hospital, Hangzhou 310022, China; Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; Harbin Medical University Cancer Hospital, Harbin 150081, China; The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China; Nanfang Medical University Nanfang Hospital, Guangzhou 510515, China; Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai 200433, China; The First Affiliated Hospital, Zhejiang University, Hangzhou 310003, China; Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China; Changzhou Fourth People's Hospital, Changzhou 213001, China; Fujian Cancer Hospital, Fuzhou 350014, China Corresponding author: Yuankai SHI, E-mail: syuankai@cicams.ac.cn DOI: 10.3779/j.issn.1009-3419.2016.07.12

[1]  B. Han,et al.  First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE). , 2016 .

[2]  Yuankai Shi,et al.  Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma , 2016, OncoTargets and therapy.

[3]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[4]  D. Lin,et al.  中国晚期原发性肺癌诊治专家共识（2016年版） , 2016, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[5]  Yunpeng Liu,et al.  Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study , 2015, PloS one.

[6]  B. Han,et al.  China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). , 2015, Journal of thoracic disease.

[7]  B. Han,et al.  A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). , 2014, Lung cancer.

[8]  S. Thongprasert,et al.  A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Ying Cheng,et al.  Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. , 2013, The Lancet. Oncology.

[11]  Quan Zhang,et al.  [Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer]. , 2012, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[12]  Ying Cheng,et al.  Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. , 2012, The Lancet. Oncology.

[13]  T. Ciuleanu,et al.  Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. , 2012, The Lancet. Oncology.

[14]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[15]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[16]  A. Gemma,et al.  F1000 highlights , 2010 .

[17]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[18]  Y. Ichinose,et al.  Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[20]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[21]  Edward S. Kim,et al.  Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Edward S. Kim,et al.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial , 2008, The Lancet.

[23]  T. Mok,et al.  Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[25]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[26]  Jinming Yu,et al.  [Standards for the diagnosis and treatment of primary lung cancer (2015 version) in China]. , 2015, Zhonghua zhong liu za zhi [Chinese journal of oncology].